跳至主要内容
临床试验/NCT00792337
NCT00792337已完成3 期

The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids in Asthma

Mahidol University1 个研究点 分布在 1 个国家目标入组 53 人开始时间: 2008年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
53
试验地点
1
主要终点
Sputum eosinophil

研究概览

简要总结

We hypothesize that simvastatin in combination with ICS might have synergistic anti-inflammatory effects on airway inflammation in asthmatic patients

详细描述

To determine the additive effect of simvastatin on airway inflammation in ICS-treated patients with persistent asthma by measuring eosinophil counts in induced sputum

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • He or she has FEV1 > 60% of predicted
  • He or she requires less than 1000 mcg daily of beclomethasone or equivalent

排除标准

  • He or she had previous history of renal disease or serum creatinine more than 2 mg/dL
  • He or she had previous history of liver disease
  • She is pregnant or during lactation
  • He or she has already received statins or is allergic to statins or has developed myositis.
  • He or she has an asthma exacerbation and requires treatment with oral corticosteroids during the 3 months prior to the commencement of study entry.

研究组 & 干预措施

simvastatin

Active Comparator

simvastatin in combination with budesonide

干预措施: simvastatin (Drug)

B1-6-12

Placebo Comparator

Budesonide in combination with B1-6-12

干预措施: B1-6-12 (Drug)

结局指标

主要结局

Sputum eosinophil

时间窗: 8 WEEKS

次要结局

  • FEV1(8 WEEKS)
  • PC20(8 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Kittipong Maneechotesuwan

Professor

Mahidol University

研究点 (1)

Loading locations...

相似试验

The Additive Anti-inflammatory Effect of Simvastatin... | 临床试验